Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice

M. Mar Rodríguez, F. Javier Pastor, Deanna A. Sutton, Enrique Calvo, Annette W. Fothergill, Valentina Salas, Michael G. Rinaldi, Josep Guarro

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

We have evaluated the in vitro activity of posaconazole (PSC) against 50 clinical strains of Rhizopus oryzae using a broth microdilution method, the Neo-Sensitabs tablet diffusion method, and minimal fungicidal concentration (MFC) determination. In general, PSC showed low MICs against this fungus, and the MICs correlated with the inhibition zone diameters. Most of the MFCs, however, were from 1 to 4 dilutions higher than their corresponding MICs. We then investigated the efficacies of several different doses of PSC in a murine model. All treatments began 24 h after challenge and lasted for 7 days. The drug was administered twice a day to mice infected with three strains that showed intermediate PSC susceptibility (MIC = 2 μg/ml) and three PSC-susceptible strains (MIC = 0.25 μg/ml). A dose of 10 mg/kg of body weight was ineffective, while doses of 20 and 30 mg/kg prolonged the survival of the mice. The 50 strains tested were segregated into two groups on the basis of the in vitro data. For the group with the most strains (85%), the strains had low PSC MICs, mice infected with the strains showed higher rates of survival (30 to 40%), and PSC was able to reduce the fungal load in the kidney and less regularly in the brain. For the second group (15% of the strains), the strains had intermediate PSC MICs, mice infected with the strains had lower survival rates (10 to 20%), and PSC treatment resulted in variable and no reductions in the fungal loads in the kidneys and brains, respectively.

Original languageEnglish (US)
Pages (from-to)1665-1669
Number of pages5
JournalAntimicrobial Agents and Chemotherapy
Volume54
Issue number5
DOIs
StatePublished - May 2010

Fingerprint

Rhizopus
Infection
Kidney
In Vitro Techniques
posaconazole
Oryza
Brain
Tablets
Fungi
Body Weight

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

Cite this

Mar Rodríguez, M., Javier Pastor, F., Sutton, D. A., Calvo, E., Fothergill, A. W., Salas, V., ... Guarro, J. (2010). Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. Antimicrobial Agents and Chemotherapy, 54(5), 1665-1669. https://doi.org/10.1128/AAC.01463-09

Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. / Mar Rodríguez, M.; Javier Pastor, F.; Sutton, Deanna A.; Calvo, Enrique; Fothergill, Annette W.; Salas, Valentina; Rinaldi, Michael G.; Guarro, Josep.

In: Antimicrobial Agents and Chemotherapy, Vol. 54, No. 5, 05.2010, p. 1665-1669.

Research output: Contribution to journalArticle

Mar Rodríguez, M, Javier Pastor, F, Sutton, DA, Calvo, E, Fothergill, AW, Salas, V, Rinaldi, MG & Guarro, J 2010, 'Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice', Antimicrobial Agents and Chemotherapy, vol. 54, no. 5, pp. 1665-1669. https://doi.org/10.1128/AAC.01463-09
Mar Rodríguez, M. ; Javier Pastor, F. ; Sutton, Deanna A. ; Calvo, Enrique ; Fothergill, Annette W. ; Salas, Valentina ; Rinaldi, Michael G. ; Guarro, Josep. / Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. In: Antimicrobial Agents and Chemotherapy. 2010 ; Vol. 54, No. 5. pp. 1665-1669.
@article{44ca7054899443fb8e6f8a2318b08c4b,
title = "Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice",
abstract = "We have evaluated the in vitro activity of posaconazole (PSC) against 50 clinical strains of Rhizopus oryzae using a broth microdilution method, the Neo-Sensitabs tablet diffusion method, and minimal fungicidal concentration (MFC) determination. In general, PSC showed low MICs against this fungus, and the MICs correlated with the inhibition zone diameters. Most of the MFCs, however, were from 1 to 4 dilutions higher than their corresponding MICs. We then investigated the efficacies of several different doses of PSC in a murine model. All treatments began 24 h after challenge and lasted for 7 days. The drug was administered twice a day to mice infected with three strains that showed intermediate PSC susceptibility (MIC = 2 μg/ml) and three PSC-susceptible strains (MIC = 0.25 μg/ml). A dose of 10 mg/kg of body weight was ineffective, while doses of 20 and 30 mg/kg prolonged the survival of the mice. The 50 strains tested were segregated into two groups on the basis of the in vitro data. For the group with the most strains (85{\%}), the strains had low PSC MICs, mice infected with the strains showed higher rates of survival (30 to 40{\%}), and PSC was able to reduce the fungal load in the kidney and less regularly in the brain. For the second group (15{\%} of the strains), the strains had intermediate PSC MICs, mice infected with the strains had lower survival rates (10 to 20{\%}), and PSC treatment resulted in variable and no reductions in the fungal loads in the kidneys and brains, respectively.",
author = "{Mar Rodr{\'i}guez}, M. and {Javier Pastor}, F. and Sutton, {Deanna A.} and Enrique Calvo and Fothergill, {Annette W.} and Valentina Salas and Rinaldi, {Michael G.} and Josep Guarro",
year = "2010",
month = "5",
doi = "10.1128/AAC.01463-09",
language = "English (US)",
volume = "54",
pages = "1665--1669",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "5",

}

TY - JOUR

T1 - Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice

AU - Mar Rodríguez, M.

AU - Javier Pastor, F.

AU - Sutton, Deanna A.

AU - Calvo, Enrique

AU - Fothergill, Annette W.

AU - Salas, Valentina

AU - Rinaldi, Michael G.

AU - Guarro, Josep

PY - 2010/5

Y1 - 2010/5

N2 - We have evaluated the in vitro activity of posaconazole (PSC) against 50 clinical strains of Rhizopus oryzae using a broth microdilution method, the Neo-Sensitabs tablet diffusion method, and minimal fungicidal concentration (MFC) determination. In general, PSC showed low MICs against this fungus, and the MICs correlated with the inhibition zone diameters. Most of the MFCs, however, were from 1 to 4 dilutions higher than their corresponding MICs. We then investigated the efficacies of several different doses of PSC in a murine model. All treatments began 24 h after challenge and lasted for 7 days. The drug was administered twice a day to mice infected with three strains that showed intermediate PSC susceptibility (MIC = 2 μg/ml) and three PSC-susceptible strains (MIC = 0.25 μg/ml). A dose of 10 mg/kg of body weight was ineffective, while doses of 20 and 30 mg/kg prolonged the survival of the mice. The 50 strains tested were segregated into two groups on the basis of the in vitro data. For the group with the most strains (85%), the strains had low PSC MICs, mice infected with the strains showed higher rates of survival (30 to 40%), and PSC was able to reduce the fungal load in the kidney and less regularly in the brain. For the second group (15% of the strains), the strains had intermediate PSC MICs, mice infected with the strains had lower survival rates (10 to 20%), and PSC treatment resulted in variable and no reductions in the fungal loads in the kidneys and brains, respectively.

AB - We have evaluated the in vitro activity of posaconazole (PSC) against 50 clinical strains of Rhizopus oryzae using a broth microdilution method, the Neo-Sensitabs tablet diffusion method, and minimal fungicidal concentration (MFC) determination. In general, PSC showed low MICs against this fungus, and the MICs correlated with the inhibition zone diameters. Most of the MFCs, however, were from 1 to 4 dilutions higher than their corresponding MICs. We then investigated the efficacies of several different doses of PSC in a murine model. All treatments began 24 h after challenge and lasted for 7 days. The drug was administered twice a day to mice infected with three strains that showed intermediate PSC susceptibility (MIC = 2 μg/ml) and three PSC-susceptible strains (MIC = 0.25 μg/ml). A dose of 10 mg/kg of body weight was ineffective, while doses of 20 and 30 mg/kg prolonged the survival of the mice. The 50 strains tested were segregated into two groups on the basis of the in vitro data. For the group with the most strains (85%), the strains had low PSC MICs, mice infected with the strains showed higher rates of survival (30 to 40%), and PSC was able to reduce the fungal load in the kidney and less regularly in the brain. For the second group (15% of the strains), the strains had intermediate PSC MICs, mice infected with the strains had lower survival rates (10 to 20%), and PSC treatment resulted in variable and no reductions in the fungal loads in the kidneys and brains, respectively.

UR - http://www.scopus.com/inward/record.url?scp=77951248570&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951248570&partnerID=8YFLogxK

U2 - 10.1128/AAC.01463-09

DO - 10.1128/AAC.01463-09

M3 - Article

C2 - 20145077

AN - SCOPUS:77951248570

VL - 54

SP - 1665

EP - 1669

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 5

ER -